Tomás Carroll

Dr. Tomás Carroll

1. Department of Medicine, Royal College of Surgeons, Dublin, Ireland
+1

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DBDavid A. Bergin
David A. Bergin
EREmer Reeves
Emer Reeves
PMPaula Meleady
Paula Meleady
MHMichael Henry
Michael Henry
OMOliver J. McElvaney
Oliver J. McElvaney
NMNoel G. McElvaney
Noel G. McElvaney
Hereditary deficiency of the protein α-1 antitrypsin (AAT) causes a chronic lung disease in humans that is characterized by excessive mobilization of neutrophils into the lung. However, the reason for the increased neutrophil burden has not been fully elucidated. In this study we have demonstrated using human neutrophils that serum AAT coordinates both CXCR1- and soluble immune complex (sIC) receptor–mediated chemotaxis by divergent pathways. We demonstrated that glycosylated AAT can bind to IL-8 (a ligand for CXCR1) and that AAT–IL-8 complex formation prevented IL-8 interaction with CXCR1. Second, AAT modulated neutrophil chemotaxis in response to sIC by controlling membrane expression of the glycosylphosphatidylinositol-anchored (GPI-anchored) Fc receptor FcγRIIIb. This process was mediated through inhibition of ADAM-17 enzymatic activity. Neutrophils isolated from clinically stable AAT-deficient patients were characterized by low membrane expression of FcγRIIIb and increased chemotaxis in response to IL-8 and sIC. Treatment of AAT-deficient individuals with AAT augmentation therapy resulted in increased AAT binding to IL-8, increased AAT binding to the neutrophil membrane, decreased FcγRIIIb release from the neutrophil membrane, and normalization of chemotaxis. These results provide new insight into the mechanism underlying the effect of AAT augmentation therapy in the pulmonary disease associated with AAT deficiency.

13 May 2003 in FEBS Letters
Verified
Journal Article
Closed access
JDJames M Devaney
James M Devaney
Catherine GreeneCatherine Greene
Catherine Greene
Clifford C. TaggartClifford C. Taggart
Clifford C. Taggart
Tomás CarrollTomás Carroll
Tomás Carroll
SOShane J O'Neill
Shane J O'Neill
NMNoel G McElvaney
Noel G McElvaney

1 February 2005 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
Catherine GreeneCatherine Greene
Catherine Greene
Tomás CarrollTomás Carroll
Tomás Carroll
SSStephen G. J. Smith
Stephen G. J. Smith
Clifford C. TaggartClifford C. Taggart
Clifford C. Taggart
JDJames Devaney
James Devaney
NMNoel G. McElvaney
Noel G. McElvaney
Cystic fibrosis (CF) is a genetic disease characterized by severe neutrophil-dominated airway inflammation. An important cause of inflammation in CF is Pseudomonas aeruginosa infection. We have evaluated the importance of a number of P. aeruginosa components, namely lipopeptides, LPS, and unmethylated CpG DNA, as proinflammatory stimuli in CF by characterizing the expression and functional activity of their cognate receptors, TLR2/6 or TLR2/1, TLR4, and TLR9, respectively, in a human tracheal epithelial line, CFTE29o−, which is homozygous for the ΔF508 CF transmembrane conductance regulator mutation. We also characterized TLR expression and function in a non-CF airway epithelial cell line 16HBE14o−. Using RT-PCR, we demonstrated TLR mRNA expression. TLR cell surface expression was assessed by fluorescence microscopy. Lipopeptides, LPS, and unmethylated CpG DNA induced IL-8 and IL-6 protein production in a time- and dose-dependent manner. The CF and non-CF cell lines were largely similar in their TLR expression and relative TLR responses. ICAM-1 expression was also up-regulated in CFTE29o− cells following stimulation with each agonist. CF bronchoalveolar lavage fluid, which contains LPS, bacterial DNA, and neutrophil elastase (a neutrophil-derived protease that can activate TLR4), up-regulated an NF-κB-linked reporter gene and increased IL-8 protein production in CFTE29o− cells. This effect was abrogated by expression of dominant-negative versions of MyD88 or Mal, key signal transducers for TLRs, thereby implicating them as potential anti-inflammatory agents for CF.

15 February 2014 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
KMKevin Molloy
Kevin Molloy
CHCraig P. Hersh
Craig P. Hersh
VMValerie B. Morris
Valerie B. Morris
Tomás CarrollTomás Carroll
Tomás Carroll
COCatherine A. O’COnnor
Catherine A. O’COnnor
NMNoel G. McElvaney
Noel G. McElvaney
Rationale: Severe α1-antitrypsin deficiency (typically PiZZ homozygosity) is associated with a significantly increased risk of airflow obstruction and emphysema but the risk of chronic obstructive pulmonary disease (COPD) in PiMZ heterozygotes remains uncertain. Objectives: This was a family-based study to determine the risk of COPD in PiMZ individuals. Methods: We compared 99 PiMM and 89 PiMZ nonindex subjects recruited from 51 index probands who were confirmed PiMZ heterozygotes and also had a diagnosis of COPD Global Initiative for Chronic Obstructive Lung Disease stage II–IV. The primary outcome measures of interest were quantitative variables of pre- and post-bronchodilator FEV1/FVC ratio, FEV1 (liters), FEV1 (% predicted), forced expiratory flow midexpiratory phase (FEF25–75; liters per second), FEF25–75 (% predicted), and a categorical outcome of COPD. Measurements and Main Results: PiMZ heterozygotes compared with PiMM individuals had a reduced median (interquartile range) post-bronchodilator FEV1 (% predicted) (92.0 [75.6–105.4] vs. 98.6 [85.5–109.7]; P = 0.04), FEV1/FVC ratio (0.75 [0.66–0.79] vs. 0.78 [0.73–0.83]; P = 0.004), and FEF25–75 (% predicted) (63.84 [38.45–84.35] vs. 72.8 [55.5–97.7]; P = 0.0013) compared with PiMM individuals. This effect was abrogated in never-smoking and accentuated in ever-smoking PiMZ individuals. PiMZ heterozygosity was associated with an adjusted odds ratio for COPD of 5.18 (95% confidence interval, 1.27–21.15; P = 0.02) and this was higher (odds ratio, 10.65; 95% confidence interval, 2.17–52.29; P = 0.004) in ever-smoking individuals. Conclusions: These results indicate that PiMZ heterozygotes have significantly more airflow obstruction and COPD than PiMM individuals and cigarette smoke exposure exerts a significant modifier effect.

1 September 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
DWDeirdre E. Walsh
Deirdre E. Walsh
Catherine GreeneCatherine Greene
Catherine Greene
Tomás CarrollTomás Carroll
Tomás Carroll
Clifford C. TaggartClifford C. Taggart
Clifford C. Taggart
PGPaula M. Gallagher
Paula M. Gallagher
NMNoel G. McElvaney
Noel G. McElvaney
Cystic fibrosis is characterized in the lungs by neutrophil-dominated inflammation mediated significantly by neutrophil elastase (NE). Previous work has shown that NE induces interleukin-8 (IL-8) gene expression and protein secretion in bronchial epithelial cells. We sought to determine the intracellular mechanisms by which NE up-regulates IL-8 in bronchial epithelial cells. The data show that stimulation of 16HBE14o− cells with NE induced IL-8 protein production and gene expression. Both responses were abrogated by actinomycin D, indicating that regulation is at the transcriptional level. Electrophoretic mobility shift assays demonstrated that nuclear factor κB (NFκB) was activated in 16HBE14o− cells stimulated with NE. Western blot analysis demonstrated that activation of NFκB by NE was preceded by phosphorylation and degradation of IκB proteins, principally IκBβ. In addition, we observed that interleukin-1 receptor-associated kinase (IRAK) was degraded in 16HBE14o− cells stimulated with NE. Quantification of IL-8 reporter gene activity by luminometry demonstrated that dominant negative MyD88 (MyD88Δ) or TRAF-6 (TRAF-6Δ) inhibited IL-8 reporter gene expression in response to NE. Furthermore, MyD88Δ inhibited NE-induced IRAK degradation. These results show that NE induces IL-8 gene up-regulation in bronchial epithelial cells through an IRAK signaling pathway involving both MyD88 and TRAF-6, resulting in degradation of IκBβ and nuclear translocation of NFκB. These findings may have implications for therapeutic treatments in the cystic fibrosis condition.

19 May 2023 in Thorax
Verified
Journal Article
Open access
PDF file
MCMichelle Casey
Michelle Casey
CGClaudie Gabillard-Lefort
Claudie Gabillard-Lefort
OMOisín F McElvaney
Oisín F McElvaney
OMOliver J McElvaney
Oliver J McElvaney
Tomás CarrollTomás Carroll
Tomás Carroll
NMNoel G McElvaney
Noel G McElvaney
Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) has been shown to improve lung function in people with cystic fibrosis (PWCF). However, its biological effects remain incompletely understood. Here we describe alterations in pulmonary and systemic inflammation in PWCF following initiation of ETI. To address this, we collected spontaneously expectorated sputum and matching plasma from PWCF (n=30) immediately prior to ETI therapy, then again at 3 and 12 months. Within 3 months, PWCF demonstrated reduced activity of neutrophil elastase, proteinase three and cathepsin G, and decreased concentrations of interleukin (IL)−1β and IL-8 in sputum, accompanied by decreasedPseudomonasburden and restoration of secretory leukoprotease inhibitor levels. Once treated with ETI, all airway inflammatory markers studied in PWCF had reduced to levels found in matched non-CF bronchiectasis controls. In PWCF with advanced disease, ETI resulted in decreased plasma concentrations of IL-6, C-reactive protein and soluble TNF receptor one as well as normalisation of levels of the acute phase protein, alpha-1 antitrypsin. These data clarify the immunomodulatory effects of ETI and underscore its role as a disease modifier.